2020 American Transplant Congress
Myeloid Derived Suppressor Cells Expanded by Granulocyte-Colony Stimulating Factor Prolong Allogeneic Cardiac Graft Survival When Compared with MDSCs Expanded by Different Means
Department of Surgery, University of Maryland, Baltimore, MD
*Purpose: Myeloid-derived suppressor cells (MDSCs) inhibit T cell responses and may provide a pathway towards tolerance. Granulocyte-colony stimulating factor (GCSF) is used in clinical practice…2020 American Transplant Congress
Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain
*Purpose: Immunobiogram (IMBG) is a new IVD bioassay developed by Biohope SL with the aim to support clinicians in the personalized adjustment of immunosuppressive therapy…2020 American Transplant Congress
Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited…2020 American Transplant Congress
Pre-Transplant Pharmacogenetics Identifies CYP3A4 and CYP3A5 Heterogeneity among Caucasian Kidney Transplant Recipients
*Purpose: Tacrolimus has always been dosed based on therapeutic drug monitoring, however pharmacogenomics is becoming increasingly more utilized in the era of precision based medicine…2020 American Transplant Congress
Targeting Th17: TIGIT as a Key Regulator of Tregs/Th17 Cells in Belatacept Resistant Rejection
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Belatacept resistant-rejection (BRR) is a major barrier to the widespread adoption of immune checkpoint blockade therapeutics in transplantation. Our lab has shown that patients…2020 American Transplant Congress
Survival after Lung Transplantation by Discharge Immunosuppressive Regimen: An Analysis of Organ Procurement and Transplantation Network Data
*Purpose: As the optimal immunosuppressive (IS) regimen after lung (LU) transplant (TX) is unknown, we conducted an analysis to compare the effect of four different…2020 American Transplant Congress
Clinical Outcomes from a Mobile Health, Pharmacist-Led Intervention: 12-Month Results of the Transafe Rx Randomized Controlled Trial
Med Univ of South Carolina, Charleston, SC
*Purpose: Medication errors and non-adherence are predominant causes of poor graft outcomes in kidney transplant (KTX) recipients. The primary aim of the TRANSAFE Rx RCT…2020 American Transplant Congress
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations
1Plexision, Pittsburgh, PA, 2Bristol-Myers-Squibb, Princeton, NJ
*Purpose: Background: Kidney recipients treated with the T-cell costimulation blocker, belatacept, experience a higher incidence of acute cellular rejection (ACR) and lower incidence of donor-specific…2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…2020 American Transplant Congress
Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia
*Purpose: Background: De novo donor specific anti-HLA antibodies (dnDSA) has profound effect on the renal graft long-term function and survival. Studies has shown identifications of…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 138
- Next Page »